Financial Performance - Opus Genetics reported a net loss of $49.6 million for the year ended December 31, 2025, compared to a net loss of $57.5 million for 2024, with an accumulated deficit of $188.6 million as of the same date[583]. - License and collaborations revenue increased to $14.2 million for the year ended December 31, 2025, up from $11.0 million in 2024, representing a growth of approximately 29.9%[602]. - Total operating expenses decreased to $52.8 million in 2025 from $73.1 million in 2024, a reduction of $20.3 million or approximately 27.8%[601]. - Research and development expenses rose to $30.8 million in 2025, compared to $26.9 million in 2024, an increase of $3.9 million or approximately 14.6%[604]. - General and administrative expenses increased to $22.0 million in 2025 from $18.2 million in 2024, a rise of $3.8 million or approximately 20.9%[605]. - For the year ended December 31, 2025, the net cash used in operating activities was $35.3 million, attributed to a net loss of $49.6 million, adjusted by non-cash operating income of approximately $16.5 million[650]. - The net cash provided by financing activities for the year ended December 31, 2025 was $50.0 million, primarily from a Registered Direct Offering of $23.0 million and a March 2025 Offering of $21.5 million[654]. Clinical Trials and Product Development - The FDA granted OPGx-LCA5 multiple designations, including Rare Pediatric Disease and Regenerative Medicine Advanced Therapy, and the program is currently in a Phase 1/2 clinical trial with six participants showing clinically meaningful vision improvements[559][560][561]. - OPGx-BEST1 received FDA clearance for an Investigational New Drug application, with the first participant dosed in a Phase 1/2 trial, and initial data expected in mid-2026[568][569]. - The Phase 3 trial for OPGx-LCA5 is expected to begin dosing in the second half of 2026, with topline clinical data anticipated approximately one year later[565]. - RYZUMVI® was approved by the FDA in September 2023, triggering a $10 million milestone payment under the Viatris License Agreement, and was commercialized in April 2024[576]. - In the VEGA-3 trial for presbyopia, 27.2% of participants treated with PS achieved a significant improvement in near visual acuity, compared to 11.5% in the placebo group (p<0.0001)[577]. - The LYNX-2 trial for treating night driving impairment met its primary endpoint, with 17.3% of participants achieving a significant improvement in low contrast distance visual acuity[578]. Funding and Cash Management - The company has funded operations primarily through equity financings, convertible notes, and milestone payments from the Viatris License Agreement, with total anticipated revenue from this agreement capped at $50 million[582][584]. - As of December 31, 2025, the company had cash and cash equivalents of $45.1 million, which is expected to fund operations for at least twelve months[614]. - The company received gross proceeds of approximately $25.0 million from a private placement in February 2026[614]. - The company plans to use proceeds from a registered direct offering, which raised approximately $23.0 million, to advance gene therapy programs and for working capital[617]. - A total of 3,827,751 shares of common stock were sold at a price of $2.09 per share, along with pre-funded warrants for 7,177,033 shares at a purchase price of $2.0899 per warrant, closing on November 7, 2025[618]. - The August 2025 Private Placement raised approximately $3.5 million by issuing 3,138,338 shares of common stock, closing on August 25, 2025[619]. - Net proceeds from the August 2025 Private Placement will be used to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1[620]. - The combined gross proceeds from the March 2025 Offering and Private Placement were approximately $21.5 million, with 862,684 warrants exercised for cash amounting to $0.8 million as of December 31, 2025[625]. - As of December 31, 2025, the company had cash and cash equivalents of $45.1 million, with total equity offerings amounting to $118.1 million and convertible notes of $8.5 million[656]. Future Outlook and Strategic Plans - The company expects higher development costs for LCA5, BEST1, and PS during later stages of clinical development due to increased trial sizes and durations[591]. - The company expects to generate significant revenue primarily from RYZUMVI® sales and regulatory approvals for LCA5 and BEST1, with no assurance of profitability or positive cash flow from operating activities[657]. - The company has budgeted research and development expenses related to the Viatris License Agreement, which are fully reimbursed, but uncertainties remain regarding the development of LCA5 and BEST1[660]. - The company anticipates satisfying its obligations through cash on hand, future equity and debt financings, and reimbursement payments until it generates adequate revenue from commercial sales[675]. Accounting and Financial Reporting - License and collaborations revenue is recognized based on the fair value of performance obligations, utilizing a discounted cash flow approach[679]. - The company has issued warrants related to March 2025 financings, recorded as liabilities at fair value, with adjustments for changes in fair value recognized in comprehensive loss[680]. - A full valuation allowance has been provided on net deferred tax assets due to uncertainty regarding future taxable income[681]. - The acquisition of in-process research and development (IPR&D) was recorded at fair value using the Multi-Period Excess Earnings Method, sensitive to changes in revenue growth rate and projected EBITDA margin[682]. - Royalties on future sales of licensed products will be expensed in the period related revenues are recognized[682]. - The company believes that recently issued accounting standards that are not yet effective will not materially impact its financial position or results of operations upon adoption[684].
Opus Genetics, Inc.(IRD) - 2025 Q4 - Annual Report